HLA-Cw*17 F 101.628-06 – including <i>Taq</i> polymerase		Page 1 of 8 General "Instructions for Use" 7. No. 00 can be downloaded from			
Lot No.: 69E Lot-s	pecific information	www.olerup.com			
<i>Olerup</i> SSP [®] HLA-Cw*17					
Product number: Lot number: Expiry date: Number of tests: Number of wells per test: Storage - pre-aliquoted primers: - PCR Master Mix: - Adhesive PCR seals - Product Insert	101.628-06 – ii 69E 2010-July-01 6 5 dark at -20°C -20°C RT RT	ncluding <i>Taq</i> polymerase			

This Product Description is only valid for Lot No. 69E.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-Cw*17 Lot

The HLA-Cw*17 primer set, specificity and interpretation tables are unchanged compared to the previous *Olerup* SSP[®] HLA-Cw*17 lot (Lot No. Y42).

Lot No.: 69E

Lot-specific information

www.olerup.com

PRODUCT DESCRIPTION

HLA-Cw*17 SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for identifying the Cw*1701 to Cw*1704 alleles.

PLATE LAYOUT

Each HLA-Cw*17 test consists of 5 PCR reactions in an 8 well cut PCR plate. Wells 6 to 8 are empty.

1	2	3	4	5	empty	empty	empty
---	---	---	---	---	-------	-------	-------

The 8 well PCR plate is marked with 'Cw*17'.

Well No. 1 is marked with the Lot No. '69E'.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

Only HLA-Cw*17 alleles will be amplified by the HLA-Cw*17 typing kit. Thus, the interpretation of HLA-Cw*17 typings is not influenced by other groups of HLA-Cw alleles or alleles of other HLA Class I loci.

UNIQUELY IDENTIFIED ALLELES

All the HLA-Cw*17 alleles, i.e. **Cw*1701 to Cw*1704**, recognized by the HLA Nomenclature Committee in April 2008¹ will be amplified by the primers in the HLA-Cw*17 SSP kit.

¹HLA-Cw alleles listed on the IMGT/HLA web page 2008-April-08, release 2.21.0, <u>www.ebi.ac.uk/imgt/hla</u>.

RESOLUTION IN HOMO- AND HETEROZYGOTES

The four HLA-Cw*17 alleles can be combined in 10 homozygous and heterozygous combinations. All these genotypes give rise to unique amplification patterns.

IFU-01 Rev. No. 00 can be downloaded from

Lot No.: 69E

Lot-specific information

www.olerup.com

SPECIFICITY TABLE

HLA-Cw*17 SSP subtyping

Specificities and sizes of the PCR products of the 5 primer mixes used for HLA-Cw*17 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA- Cw*17 alleles	Other amplified HLA-Cw alleles
1	350 bp	800 bp	1701, 1703, 1704 [?]	
2 ³	70 bp	1070 bp	1702, 1704 [?]	
3	300 bp	1070 bp	1703, 1704 [?]	
4 ³	90 bp	1070 bp	1701, 1704 [?]	
5	155 bp	1070 bp	1704	

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-Cw*17 SSP typings.

When the primers in a primer mix can give rise to specific PCR products of more than one length this is indicated if the size difference is 20 base pairs or more. Size differences shorter than 20 base pairs are not given. For high resolution SSP kits the respective length of the specific PCR product(s) of the alleles amplified by these primer mixes are given.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-Cw*17 SSP subtyping.

In the presence of a specific amplification the intensity of the control band often decreases.

³Short specific PCR fragments are less intense and not as sharp as longer specific bands.

"?', nucleotide sequence information not available for the primer matching sequence.

General "Instructions for Use" IFU-01 Rev. No. 00 can be downloaded from

Lot No.: 69E

Lot-specific information

www.olerup.com

INTERPRETATION TABLE							
HLA-Cw*17 SSP subtyping							
Amplification patterns of the HLA-Cw*17 alleles							
			Well				
	1	2	3	4	5		
Length of spec.	350	70	300	90	155	Length of spec.	
PCR product						PCR product	
Length of int.	800	1070	1070	1070	1070	Length of int.	
pos. control ¹						pos. control ¹	
5'-primer ²	20	28	70	20	126	5'-primer ²	
	^{5'} -CCA ^{3'}	^{5'} -TCA ^{3'}	^{5'} -ggA ^{3'}	^{5'} -CCA ^{3'}	^{5'} -ggA ^{3'}		
3'-primer ³	201	59	201	70	239	3'-primer ³	
	5'-CTC ^{3'}	^{5'} -CgA ^{3'}	5'-CTC ^{3'}	⁵ '-ggC ^{3'}	^{5'} -gCg ^{3'}		
Well No.	1	2	3	4	5	Well No.	
HLA-Cw allele						HLA-Cw allele	
*1701	1			4		*1701	
*1702		2				*1702	
*1703	1		3			*1703	
*1704	?	?	?	?	5	*1704	
HLA-Cw allele						HLA-Cw allele	
Well No.	1	2	3	4	5	Well No.	

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control

band in order to help in the correct orientation of the HLA-Cw*17 SSP subtyping. ²The nucleotide position, in the 1st exon or 2nd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the <u>www.ebi.ac.uk/imgt/hla</u> web site. The sequence of the 3 terminal nucleotides of the primer is given. ³The nucleotide position, in the 1st or 2nd exon, matching the specificity-determining 3'-end of the

primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

??, nucleotide sequence information not available for the primer matching sequence.

Page 5 of 8 General "Instructions for Use" IFU-01 Rev. No. 00 can be downloaded from

Lot No.: 69E

Lot-specific information

www.olerup.com

CELL LINE VALIDATION SHEET									
HLA-Cw*17 SSP primer set									
							We		2
					1	2	3	4	5
					-	N	6	4	5
					200847301	200847302	200847303	200847304	200847305
				Prod. No.	347	347	347	347	347
				l õ	ğ	lõ	lõ	ğ	lõ
_					2	й	й	ñ	ñ
_		VC cell line	-	Cw*		_	_		
1	9001		*0702	*1=0=	-	-	-	-	-
2		LK707	*0701	*1505	-	-	-	-	-
3		E4181324	*1202		-	-	-	-	-
4		GU373	*0304	*0401	-	-	-	-	-
5		KAS011	*0602		-	-	-	-	-
6	9353		*0304	*0702	-	-	-	-	-
7	9020		*0501		-	-	-	-	-
8	9007		*0602		-	-	-	-	-
9		YAR	*1203		-	-	-	-	-
10		LKT3	*0102		-	-	-	-	-
11		PITOUT	*1601		-	-	-	-	-
12	9052		*0602		-	-	-	-	-
13	9067		*0102		-	-	-	-	-
14		OLGA	*0102	*0304	-	-	-	-	-
15	9075		*0304		-	-	-	-	-
16	9037		*0202		-	-	-	-	-
17		WILJON	*1203		-	-	-	-	-
18	9257	32367	*0102	*0705	-	-	-	-	-
19	9038	BM16	*0701		-	-	-	-	-
20	9059	SLE005	*0304		-	-	-	-	-
21		AMALA	*0303		-	-	-	-	-
22	9056	KOSE	*1203		-	-	-	-	-
23	9124	IHL	*0102	*1502	-	-	-	-	-
24	9035	JBUSH	*1203		-	-	-	-	-
25	9049	IBW9	*0802		-	-	-	-	-
26	9285	WT49	*0701		-	-	-	-	-
27	9191	CH1007	*0704	*1505	-	-	-	-	-
28	9320	BEL5GB	*0501	*1601	-	-	-	-	-
29	9050	MOU	*1601		-	-	-	-	-
30	9021	RSH	*1701		+	-	-	+	-
31	9019	DUCAF	*0501		-	-	-	-	-
32	9297	HAG	*1701	*1703	+	-	+	-	-
33	9098	MT14B	*0304		-	-	-	-	-
34	9104	DHIF	*1203		-	-	-	-	-
35	9302	SSTO	*0501		-	-	-	-	-
36	9024	KT17	*0303	*0401	-	-	-	-	-
37	9065	HHKB	*0702		-	-	-	-	-
38	9099	LZL	*0303		-	-	-	-	-
39	9315		*0202	*0701	-	-	-	-	-
40	9134	WHONP199	*0602		- 1	-	-	-	-
41	9055	H0301	*0802		-	-	-	-	-
42		TAB089	*0102		-	-	-	-	-
43		T7526	*0102	*0801	- 1	-	-	-	-
44	9057		*1203		-	-	-	-	-
45		SHJO	*0602	*1701	+	-	-	+	-
46		SCHU	*0702		-	-	-	-	-
47		TUBO	*0704	*1502	- 1	-	-	-	-
48		TER-ND	*0401	*1601	-	-	-	-	-
	0000				I				-

IFU-01 Rev. No. 00 can be downloaded from

Lot No.: 69E

Lot-specific information

www.olerup.com

CERTIFICATE OF ANALYSIS

Olerup SSP [®] HLA-Cw*17 SSP	
Product number:	101.628-06 – including <i>Taq</i> polymerase
Lot number:	69E
Expiry date:	2010-July-01
Number of tests:	6
Number of wells per test:	5

Well specifications:

Well No.	Production No.
1	2008-473-01
2	2008-473-02
3	2008-473-03
4	2008-473-04
5	2008-473-05

The specificity of each primer solution of the HLA-Cw*17 primer set has been tested against 48 well characterized IHWC cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 2 and 5 were available. The specificity of the primers in primer solution 2 were tested by separately adding one additional 5'-primer, respecitively one additional 3'primer. In primer solution 5 it was only possible to test the 5'-primer, the 3'primer was not possible to test.

Results: No false positive or false negative amplifications were obtained.

Date of approval: 2009-May-26

Approved by:

Quality Control, Supervisor

Lot No.: 69E

Lot-specific information

www.olerup.com

Declaration of Conformity

Product name: Product number: Lot number:	<i>Olerup</i> SSP [®] HLA_Cw*17 101.628-06 69E
Intended use:	HLA-Cw*17 high resolution histocompatibility testing
Manufacturer:	<i>Olerup</i> SSP AB Hasselstigen 1 SE-133 33 Saltsjöbaden, Sweden <i>Phone:</i> +46-8-717 88 27 <i>Fax:</i> +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2000 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex III, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

The Authorized Representative located within the Community is: *Olerup* SSP AB.

Saltsjöbaden, Sweden 2009-May-26

Olle Olerup Managing Director Lot No.: 69E

Lot-specific information

www.olerup.com

ADDRESSES:

Manufacturer: *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden. *Tel:* +46-8-717 88 27 *Fax:* +46-8-717 88 18 *E-mail:* info-ssp@olerup.com *Web page:* http://www.olerup.com

Distributed by: Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria. *Tel:* +43-1-710 15 00 *Fax:* +43-1-710 15 00 10 *E-mail:* support-at@olerup.com *Web page:* http://www.olerup.com

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382 *Tel:* 1-877-OLERUP1 *Fax:* 610-344-7989 *E-mail:* info.us@olerup.com *Web page:* http://www.olerup.com

For information on Olerup SSP distributors worldwide, contact Olerup GmbH.